Patient Advocate Michael Betel of the Fatty Liver Alliance joins Roger Green to discuss the presentations, events and themes of TLM 2023 he found most empowering for patients and advocates.
Dr. Tim Jobson of Predictive Health Intelligence joins Roger Green in our continuing TLM2023 coverage. Tim and Roger discussing PHI’s work in data-based identification of patients who are not receiving needed treatment and how this pertains to the vast global need for MASLD screening.
Dr. Zobair Younossi joins Roger Green to kick off our review coverage of TLM 2023. Dr. Younossi discusses the studies he presented at the meeting and discusses other work related to patient quality-of-life, economics of screening and treatment, and how stigma affects both patients and providers.
Previewing The Liver Meeting 2023: Last week’s posting consisted of 1:1 interviews with four KOL from different spheres, each talking with Roger Green about what they are looking forward to seeing at this week’s The Liver Meeting 2023. This week, two of those KOLs, co-host Jörn Schattenberg and hepatology KOL Naim Alkhouri, join Roger and co-host Louise Campbell, FRCP, in a free-wheeling review of key abstracts that will be presented at TLM2023.
This week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about the Liver Meeting 2023 (held in Boston from November 10 – 14) and much more. In this conversation, Key Opinion Leader, Scott Isaacs, joins to discuss this highly anticipated event as well as offer a glimpse into his current work and research interests.
This week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about the Liver Meeting 2023 (held in Boston from November 10 – 14) and much more. In this conversation, friend of the podcast, Naim Alkhouri, joins to discuss this highly anticipated event as well as offer a glimpse into his current work and research interests.
This week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about anticipations around the Liver Meeting 2023 (held in Boston from November 10 – 14) and much more. In this session, President of the Fatty Liver Alliance, Michael Betel, joins to discuss this highly anticipated event, plus some additional key ideas around patient advocacy.
This week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about the Liver Meeting 2023 (held in Boston from November 10 – 14) and much more. In this first conversation, Jörn Schattenberg joins to discuss this highly anticipated event as well as offer a glimpse into his current work and research interests.
This conversation From the Vault reprises our earlier interview from June with Tetiana Deshko, Director of Programs for the Alliance for Public Health in Ukraine.
In continuation of the Surfing NASH interview series, Roger Green talks to Professor Oren Shibolet, Head of Gastroenterology and Hepatology at the Tel Aviv Medical Center, and the impact of war.
In continuation of the Surfing NASH interview series, Roger Green talks to Professor Oren Shibolet, Head of Gastroenterology and Hepatology at the Tel Aviv Medical Center.
In continuation of the Surfing NASH interview series, this week Roger Green talks to Professor Oren Shibolet, Head of Gastroenterology and Hepatology at the Tel Aviv Medical Center.
In continuation of the Surfing NASH interview series, this week Roger Green talks to Professor Oren Shibolet, Head of Gastroenterology and Hepatology at the Tel Aviv Medical Center.
In this conversation, Ian Rowe describes the factors that motivated him and Richard Parker to build a decision model focusing on early NASH diagnosis. He identifies three data points demonstrating how severely NASH stakeholders need a better early diagnosis paradigm and then describes the five diagnostic strategies his model will test.
This final conversation covers the other paper discussed in the episoe at large, a literature review looking at how MASH and MASLD might differ in women compared to men. Roberta starts by noting the gap in literature about gender differences in MASH studies, and that women appear represented in most clinical trials.
This conversation starts with Roger asking Roberta to describe the demographics of the population in the northwest London region where the study of interest was done. Roberta comments on the robust diversity of the population, after which Louise amplifies this point by noting the large number of Arabic and South Asian patients in the study population.
This conversation starts with your Jörn returning to a key point from Roberta’s paper around a 38% false negative rate for FIB-4 screening. Jörn notes that while this feels like a high rate for false negatives, it might not present as much of a diagnostic challenge if treaters repeat the screening every 2 to 3 years.
This week on SurfingNASH, we introduce the audience to new guest, Dr Roberta Forlano, who’s been awarded an EASL Juan Rodes PhD Fellowship and has completed a PhD in Translational Hepatology at Imperial College London in 2022.
In a recent SurfingNASH episode, Dr. Roberta Forlano, celebrated for her hepatology research and EASL Juan Rodes PhD Fellowship, delves into critical aspects of NAFLD, from screening strategies in primary care to non-invasive markers, alongside experts Jörn Schattenberg, Louise Campbell, and Roger Green. The discussions, centered on screening strategies for gender-specific SLD challenges, also showcase Roberta’s team’s notable contributions to the SLD Summit. A must-listen for those interested in advanced hepatology topics and research developments.
This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.
This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.
This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.
This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.
This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.
This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.
This episode From the Vault comes from last year’s SurfingNASH review of the 2022 NAFLD Summit with Mazen Noureddin, Sven Francque and Hannes Hagström.
The 2022 NAFLD Summit uniquely presented a range of perspectives and insights on fatty liver and metabolic diseases.
The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD. In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.
This week, SurfingNASH offers an episode comprising two separate interviews which focus on stories around career trajectories, transitions and entrepreneurship.
The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.
In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.
The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.
In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.
The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.
In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.
The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.
In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.
Surfing NASH reviews the 2023 EASL SLD Summit in two interview sessions with meeting faculty members Sven Francque and Hannes Hagström. Co-host Jörn Schattenberg joins both conversations as a fellow presenter while Louise Campbell and Roger Green inject thought-provoking questions and perspectives to elicit a succinct snapshot of the event for our listeners.
In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!
In this final conversation, the Surfers are joined by Veronica Miller to discuss the recent FDA workshop for NIT development. Veronica discusses her unique impressions on the workshop and steers the group to consider the question of “why are we validating a surrogate with a surrogate?”
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. This discussion largely focuses on ideas around distinguishing the difference between NITs to qualify patients for trials versus to evaluate efficacy of drugs.
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. Laurent focuses on why this workshop is important within its context of being hosted by the FDA and what that means for researchers and stakeholders across the globe. He also dives into the complexities of hepatocellular ballooning and its potential impact on patients receiving NASH pharmacotherapy.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. The group discusses loss aversion, screen fail rates, the future of FDA decision making and more.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. Naim expands on ideas around an NIT-based alternative path to conditional approval as well as provides a general survey of how the workshop played out as he served as an expert panelist in Tuesday’s penultimate session.
The Surfers are joined by Naim Alkhouri, Laurent Castera and Veronica Miller in three distinct interviews on the topic of the recent FDA workshop around NIT development and the future of the field.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating final conversation which raises new and interesting topics covered at the event.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a conversation around the complex challenges in adequately assessing and treating patients.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. In this conversation, presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green to ask and answer questions surrounding the task of testing patients for optimized results under different scenarios.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating conversation that dives deeper into emerging questions surrounding the use of NITs in a landscape which features drug approval.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating session that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. This opening conversation highlights the different presentations delivered by the guests followed by discussion around the liver as a regenerative organ and the use and limitations of NITs.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for an exciting episode that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. Surf on to learn much more from what always pans out to be an incredibly in-depth and insightful event.
Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This final session considers a few more populations who might benefit from such a test before the panelists field a final question that speculates what MASEF will look like 2 years from today.
Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This conversation considers applying the test to pediatric populations and the newly classified Met-ALD population (those with MASLD who consume greater amounts of alcohol per week). Additionally, the group considers what’s next for MESAF and how metabolomic tests are becoming commercially available in different countries.
In this conversation, Mazen Noureddin fields questions from Jörn Schattenberg, Louise Campbell and Roger Green around different application settings for the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). The group discusses pros and cons of different approaches and speculate on challenges such as cost effectiveness and ease of use.
In this conversation, Mazen Noureddin introduces his recent work around serum identification of at-risk MASH and the recent paper he co-authored on the subject. He describes the aims of the study as well as provides a cogent background for why this work came to be and maintains its relevance.
Surfing NASH returns to its regular program with a fresh episode and some fascinating and progressive ideas on non-invasive testing with Mazen Noureddin. For this feature, Mazen talks about his recent work in serum identification of at-risk MASH and the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) respond with their thoughts and varying perspectives.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment features ideas around how health care systems can improve and important lessons learned from the COVID pandemic.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment focuses on the importance of team work and the strengths that multidisciplinary approaches can provide when supporting patients.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment introduces three important questions that the group aims to answer throughout the wider episode.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
What do liver nursing KOLs see as the largest, most important changes they can hope for 2-3 years from now?
How does the misalignment of liver patients’ needs and nursing availability limit chances to intervene early in the course of Fatty Liver disease?
Nursing KOLs discuss the extensive backgrounds and diverse skill sets they bring to the challenge of educating Fatty Liver patients early in disease progression.
This week, Surfing NASH looks back at a Season 3 episode that remains particularly relevant in light of recent stories on new nomenclature and therapeutic developments for liver disease. An all-star panel of liver nurses and advanced nurse practitioners join Louise Campbell and Stephen Harrison to explore the myriad ways allied health experts can play a broader role in NASH education and patient management.
Ian Rowe, Louise Campbell and Roger Green discuss two issues in NASH patient management: the number of patients that are told they have Fatty Livers not to worry about treating it, and the general challenges in treating patients whose NASH is part of a constellation of metabolic diseases.
New guest, Prof. James O’Breine, joins Naim Alkhouri, Louise Campbell and Roger Green to discuss improving models for patient identification and risk stratification with the LOCATE-NAFLD project. This final conversation addresses the importance of adequate training in order to optimize the potential of advancing technologies. For final questions, James shares what’s next for the project and the other panelists discuss takeaways from this discussion in terms of improving screening or cost effectiveness.
New guest, Prof. James O’Breine, joins Naim Alkhouri, Louise Campbell and Roger Green to discuss improving models for patient identification and risk stratification with the LOCATE-NAFLD project. This conversation focuses on questions around funding before moving on to consider the importance of generating and managing the best sets of data. As the conversation concludes, the group discusses concerns over consistency of scan reads and shares tips on how to get a more accurate measurement.
New guest, Prof. James O’Breine, joins Naim Alkhouri, Louise Campbell and Roger Green to discuss improving models for patient identification and risk stratification with the LOCATE-NAFLD project. This conversation focuses on details of the study design related to cost effectiveness, scalability and feasibility when looking to implement in other countries.
New guest, Prof. James O’Breine, joins Naim Alkhouri, Louise Campbell and Roger Green to discuss improving models for patient identification and risk stratification with the LOCATE-NAFLD project. This conversation features general comments and questions around the study design before James shares two interesting pieces of data from early analysis.
